Taysha Gene Therapies (TSHA) Cash from Investing Activities (2020 - 2026)

Taysha Gene Therapies has disclosed Cash from Investing Activities across 7 years of filings, most recently posting -$3.0 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$3.0 million, down 715.09% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 448.32% YoY), and the FY2025 annual result was -$604000.0, down 66.39% from the prior year.
• Cash from Investing Activities came in at -$3.0 million for Q1 2026 at Taysha Gene Therapies, down from -$247000.0 in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $62000.0 in Q2 2025 to a low of -$11.4 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$247000.0 (2025), against an average of -$2.1 million.
• Across the five-year window, Cash from Investing Activities sank 2039.89% in 2022 and soared 230.0% in 2024, its largest moves.
• Taysha Gene Therapies' Cash from Investing Activities stood at -$2.4 million in 2022, then jumped by 99.58% to -$10000.0 in 2023, then jumped by 230.0% to $13000.0 in 2024, then sank by 2000.0% to -$247000.0 in 2025, then tumbled by 1124.29% to -$3.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$3.0 million (Q1 2026), -$247000.0 (Q4 2025), and -$48000.0 (Q3 2025), per Business Quant data.